Newcastle Clinical Trials Unit

TALGITS

TALGiTS

A pragmatic, multicentre, placebo controlled, double blind, parallel, randomised controlled trial of liquid alginate (Gaviscon Advance) for the treatment of persistent throat symptoms

  • Study Stage: Recruiting
  • Sponsor:  The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Funder:  IIT (Reckitt)
  • Therapeutic area: Ear, Nose and Throat
  • Type of study: CTIMP

Aim: To compare the symptomatic response in patients with persistent throat symptoms to a liquid alginate (Gaviscon Advance) compared to matched placebo.

Primary Outcome: Total Reflux Symptom Index (RSI) score at 8 weeks

  • Population: Adult
  • Design: RCT (double-blind)
  • Setting: Secondary Care
  • Phase:  III
  • Planned Sample Size: 250